News

And while 2023 brought the development of a monoclonal antibody for infants, a type of passive immunization that provides short-term protection from RSV, there has yet to be an actual RSV vaccine for ...
The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna shares were up 5.9% on Wednesday, while Pfizer was up 1%. GSK’s American ...
A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...
Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...
Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years down the road, potentially benefit from a huge biotech growth story.
The FDA has expanded the use of Moderna's respiratory syncytial virus (RSV) shot to all adults, with some limits on who can get it.
Moderna's RSV vaccine is based on mRNA technology, which some of the new members have expressed skepticism about, especially in relation to COVID-19 vaccines.
Moderna intends to have mRESVIA available for both younger adults at increased risk (ages 18-59) and older adults (ages 60+) in the U.S. for the 2025-2026 respiratory virus season.
Moderna intends to have mRESVIA available for both younger adults at increased risk (ages 18-59) and older adults (ages 60+) in the U.S. for the 2025-2026 respiratory virus season.
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease Written by moderna inc.